NCT00000845View on ClinicalTrials.gov

A Phase I Safety and Immunogenicity Trial of UBI HIV Lipopeptide Vaccine Component P3C541b in HIV-1 Seronegative Human Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

30

Participants

Timeline

Start Date

Not specified

Conditions

HIV Infections

Interventions

BIOLOGICAL

P3C541b Lipopeptide

Trial Locations (3)

37232

Vanderbilt Univ Hosp, Nashville

98144

Univ of Washington / Pacific Med Ctr, Seattle

212051901

Johns Hopkins Univ / School of Hygiene & Public Health, Baltimore

All Listed Sponsors

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH